Local AP-1 Inhibitor Delivery for Postsurgical Adhesion Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no effective treatments available to prevent or reduce the formation of adhesions, which are fibrotic scars that form between abdominal organs following surgery, causing bowel obstruction, chronic pain, or infertility, affecting a significant portion of surgical patients worldwide.
Innovation Solution
The use of a small molecule inhibitor of the Activator Protein 1 (AP-1) transcription factor complex, T-5224, administered locally at the surgical site, either alone or in combination with other active agents, to inhibit adhesion formation, potentially delivered through biodegradable implants or sustained release formulations like PLGA particles or liposomal particles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no treatment is applied, then adhesion formation occurs in 50-90% of surgical patients, but there are no available treatments to prevent adhesions
Solution Approach 1:
The patent changes the molecular parameter by introducing T-5224, a small molecule inhibitor that specifically targets the AP-1 transcription factor complex. This compound binds to and inhibits c-Jun and c-Fos proteins, preventing the profibrotic signaling cascade that leads to adhesion formation. The specific molecular mechanism involves blocking AP-1-mediated gene expression of fibrotic markers such as collagen and alpha-smooth muscle actin, thereby preventing adhesion formation with high efficacy.
2Reliability
If AP-1 inhibitor is administered systemically, then adhesion prevention may be achieved, but off-target effects and toxicity increase
Solution Approach 1:
The patent applies the inhibitor locally at the surgical site rather than systemically. The composition is applied directly to the peritoneal surface during surgery, creating a localized high concentration of the drug precisely where adhesion formation is initiated. This local application ensures potent inhibition of AP-1 signaling in adhesion fibroblasts at the target site while minimizing systemic exposure and potential off-target effects on other tissues and organs.
Solution Approach 2:
The patent uses biodegradable polymers such as PLGA (poly(lactic-co-glycolic acid)) as intermediary carriers to deliver the AP-1 inhibitor. These polymer particles or implants provide sustained local release of T-5224 over time, maintaining therapeutic concentrations at the surgical site without requiring repeated systemic administration. The biodegradable nature of the polymer ensures safe degradation into non-toxic byproducts (lactic acid and glycolic acid) that are metabolized by the body.
3Ease of operation
If single dose administration is used, then treatment simplicity increases, but sustained inhibition of profibrotic signaling is insufficient
Solution Approach 1:
The patent implements periodic action through sustained-release formulations that deliver the AP-1 inhibitor over an extended period. The biodegradable polymer particles or implants release T-5224 in a controlled, periodic manner, maintaining therapeutic levels throughout the critical adhesion formation window (typically 1-14 days post-surgery). This sustained release profile ensures continuous inhibition of profibrotic signaling without requiring multiple manual administrations, thus balancing treatment simplicity with adequate duration of action.
Data Source
Figure 1a~1d
Figure 1e~1g
Figure 2a~2c
AI summary
Aspects of the present disclosure include methods of treating a subject to reduce adhesion formation.